SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-22-029279
Filing Date
2022-12-16
Accepted
2022-12-16 17:10:18
Documents
15
Period of Report
2022-12-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dffn20221215_8k.htm   iXBRL 8-K 36583
2 EXHIBIT 10.1 ex_457161.htm EX-10.1 123685
3 EXHIBIT 99.1 ex_457162.htm EX-99.1 15506
  Complete submission text file 0001437749-22-029279.txt   336156

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA dffn-20221215.xsd EX-101.SCH 3602
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dffn-20221215_def.xml EX-101.DEF 11533
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE dffn-20221215_lab.xml EX-101.LAB 15415
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dffn-20221215_pre.xml EX-101.PRE 11689
9 EXTRACTED XBRL INSTANCE DOCUMENT dffn20221215_8k_htm.xml XML 2606
Mailing Address 300 EAST MAIN STREET SUITE 201 CHARLOTTESVILLE VA 22902
Business Address 300 EAST MAIN STREET SUITE 201 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

IRS No.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37942 | Film No.: 221468801
SIC: 2834 Pharmaceutical Preparations